Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Studies from University of Colorado in the area of melanoma published
January 27th, 2009
According to recent research published in the American Journal of Health - System Pharmacy, "New medications and combination treatment strategies for patients with metastatic melanoma are discussed. Bcl-2 is an inhibitor of apoptosis that is overexpressed in approximately 80% of melanoma cell lines and is believed to contribute to the development of resistance to cytotoxic chemotherapy in patients with melanoma." "Oblimersen, an antisense oligonucleotide that stops the translation of Bcl-2 mRNA to protein, significantly improved progression-free survival when administered in combination with dacarbazine. Overall survival was significantly improved in patients...
Source: Cancer Weekly (2009-01-27)
|
